CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Vanderbilt University · Brigham and Women's Hospital · +2 more institutions
Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. However, CAR immunotherapy in solid tumors lags significantly behind. Some of the major hurdles for CAR immunotherapy in solid tumors include CAR T cell manufacturing, lack of tumor-specific antigens, inefficient CAR T cell trafficking and infiltration into tumor sites, immunosuppressive tumor microenvironment (TME), therapy-associated toxicity, and antigen escape. CAR Natural Killer (NK) cells have several advantages over CAR T cells as the NK cells can be manufactured from pre-existing cell lines or…
Citation impact
- FWCI
- 59.28
- Percentile
- 100%
- References
- 108
Authors
6- KPKevin PanCorresponding
Vanderbilt University
- HFHizra Farrukh
Brigham and Women's Hospital, Harvard University
- VCVeera Chandra Sekhar Reddy Chittepu
Brigham and Women's Hospital, Harvard University
- HXHuihong Xu
VA Boston Healthcare System
- CPChong-xian Pan
Brigham and Women's Hospital, Harvard University, VA Boston Healthcare System
Topics & keywords
- Chimeric antigen receptor
- Immunotherapy
- Immunology
- Cell therapy
- Tumor microenvironment
- Cancer immunotherapy
- Adoptive cell transfer
- Medicine
- Good health and well-being